Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (129)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (13)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)
    Meeting Abstract

    Colevas, A. D.; Chung, C. H.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Sukari, A.; Worden, F. P.; Johnson, F. M.; Saba, N. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1 safety and efficacy of IMC-F106C, a PRAME x CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
    Meeting Abstract

    Hamid, O.; Williams, A.; Lopez, J. S.; Olson, D.; Sato, T.; Shaw, H. M.; Friedman, C. F.; Thistlethwaite, F.; Middleton, M. R.; Lebbe, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
    Meeting Abstract

    Chandana, S. R.; Choudhury, N. J.; Dowlati, A.; Chiang, A. C.; Garmezy, B.; Kim, J. H.; Byers, L. A.; Ahn, M. J.; Kim, T. M.; Kim, Y. C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C
    Meeting Abstract

    Sun, L.; Fayette, J.; Salas, S.; Hong, D. S.; Adkins, D.; Dunn, L.; Ciardiello, F.; Cirauqui, B.; William, W. N. Jr; Saba, N. F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • International medical graduates (IMG) representation at international oncology conference meetings
    Meeting Abstract

    Roy, A. M.; Bakouny, Z.; Dizman, N.; Ozay, Z. I.; Lal, B. M.; Nawfal, R.; Eid, M.; Chehade, R. E.; Machaalani, M.; Butt, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Meeting Abstract

    Beltran, H.; Johnson, M. L.; Jain, P.; Schenk, E. L.; Sanborn, R. E.; Thompson, J. R.; Dowlati, A.; Mamdani, H.; Aggarwal, R. R.; Anand, B. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Meeting Abstract

    Funt, S. A.; Grivas, P.; Gao, X.; Vaena, D. A.; Zhang, T.; Milowsky, M. I.; Rao, M.; Liu, H.; Tipton, K.; An, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Meeting Abstract

    Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer
    Meeting Abstract

    Gaillard, S.; Starodub, A.; O'Neil, B.; Mathews, C. A.; Dumbrava, E. E.; Friedman, C. F.; Swiecicki, P.; Oh, C.; Andreu, C.; Lee, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save